cilostazol vs nirmatrelvir/ritonavir
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of cilostazol and nirmatrelvir/ritonavir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
cilostazol ↑ cilostazol Dosage adjustment of cilostazol is recommended. Refer to the cilostazol product label for more information.
Pletal
Paxlovid
Cilostazol is a medicine that helps improve walking distance in people with leg pain due to poor circulation. It works by helping blood flow more easily through your blood vessels.
Paxlovid is a medicine used to treat mild to moderate COVID-19 in adults. It helps prevent severe illness, hospitalization, or death in people at high risk.
Cilostazol treats intermittent claudication. This is leg pain that happens when you walk because your leg muscles are not getting enough blood. Cilostazol helps to reduce the symptoms of this condition, like leg pain, by improving blood flow to your legs, so you can walk further without pain.
Paxlovid treats mild to moderate COVID-19 in adults. You must be at high risk of your illness becoming severe. This includes needing to go to the hospital or possibly dying from COVID-19. Paxlovid is not for preventing COVID-19 before or after exposure.
Cilostazol is a phosphodiesterase III (PDE III) inhibitor. It works by relaxing the muscles in your blood vessels. This helps more blood flow to your legs and feet.
Paxlovid contains two medicines, nirmatrelvir and ritonavir. Nirmatrelvir stops the virus from multiplying in your body. Ritonavir helps nirmatrelvir stay in your body longer so it can work better.
- • Headache
- • Diarrhea
- • Abnormal stools
- • Palpitation (feeling your heart beat)
- • Dizziness
- • Change in taste
- • Diarrhea
- Diarrhoea 302
- Fall 231
- Pneumonia 230
- Death 217
- Dyspnoea 209
- COVID-19 22,774
- COVID-19 coming back 20,089
- Change in taste 7,316
- Diarrhea 4,003
- Feeling sick to your stomach 2,620
You should not take cilostazol if you have heart failure. This medicine can be harmful if you have heart failure.
Paxlovid can interact with many other medicines, causing serious or life-threatening problems. Before taking Paxlovid, tell your doctor about all the medicines you take. Your doctor may need to adjust the dose of your other medicines or monitor you more closely.
It is not known if cilostazol is safe to take during pregnancy. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if cilostazol passes into breast milk. You should not breastfeed while taking cilostazol.
There is not enough information about nirmatrelvir's safety during pregnancy. Studies on ritonavir in pregnant women have not shown an increased risk of birth defects. Talk to your doctor about the risks and benefits of taking Paxlovid if you are pregnant or breastfeeding.
How to Read This cilostazol vs nirmatrelvir/ritonavir Comparison
cilostazol is classified in the PDE3 Inhibitor (Antiplatelet) drug class, while nirmatrelvir/ritonavir sits within the Antiviral (Protease Inhibitor Combination) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, cilostazol has 1,189 submissions while nirmatrelvir/ritonavir has 56,802. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to ritonavir prevents the body from clearing cilostazol normally, which leads to higher and potentially unsafe levels of the drug in your system.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for cilostazol or nirmatrelvir/ritonavir.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.